WHO Expert Committee on Biological Standardization: fifty-second report
Gespeichert in:
| Körperschaft: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Geneva
World Health Organization
2004
|
| Schriftenreihe: | Technical report series (World Health Organization)
924 |
| Schlagworte: | |
| Beschreibung: | "The WHO Expert Committee on Biological Standardization met in Geneva from 26 to 30 November 2001"--Introd Includes bibliographical references |
| Beschreibung: | vii, 232 p. |
| ISBN: | 9241209240 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV044122737 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170217s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9241209240 |9 92-4-120924-0 | ||
| 035 | |a (ZDB-30-PAD)EBC284745 | ||
| 035 | |a (ZDB-89-EBL)EBL284745 | ||
| 035 | |a (OCoLC)317384275 | ||
| 035 | |a (DE-599)BVBBV044122737 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 615.1901 |2 22 | |
| 110 | 2 | |a WHO Expert Committee on Biological Standardization |b Meeting < 2001, Geneva, Switzerland> |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a WHO Expert Committee on Biological Standardization |b fifty-second report |
| 264 | 1 | |a Geneva |b World Health Organization |c 2004 | |
| 300 | |a vii, 232 p. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Technical report series (World Health Organization) |v 924 | |
| 500 | |a "The WHO Expert Committee on Biological Standardization met in Geneva from 26 to 30 November 2001"--Introd | ||
| 500 | |a Includes bibliographical references | ||
| 505 | 0 | |a 505 0 Introduction -- General. Developments in biological standardization. Bioterrorism. International nonproprietary names for biotechnology-derived medicinal products -- International guidelines, recommendations, and other matters related to the manufacture and quality control of biologicals. Guidelines on clinical evaluation of vaccines: regulatory expectations. Group C meningococcal conjugate vaccines. Inactivated oral cholera vaccines. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. Pneumococcal conjugate vaccines. Potency assays for diphtheria and tetanus vaccines. Pertussis vaccines. Preventive human immunodeficiency virus vaccines. Cell substrate safety. Cell banks. Yellow fever. Poliomyelitis vaccine, oral. Transmissible spongiform encephalitis and the safety of biologicals. Antivenoms. Gene therapy. Discontinuation requirements -- | |
| 650 | 4 | |a Biological products |x Standards |v Congresses | |
| 650 | 4 | |a Drugs |x Standards |v Congresses | |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 912 | |a ZDB-30-PAD | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029529582 | ||
Datensatz im Suchindex
| _version_ | 1804177204849934336 |
|---|---|
| any_adam_object | |
| author_corporate | WHO Expert Committee on Biological Standardization Meeting < 2001, Geneva, Switzerland> |
| author_corporate_role | aut |
| author_facet | WHO Expert Committee on Biological Standardization Meeting < 2001, Geneva, Switzerland> |
| author_sort | WHO Expert Committee on Biological Standardization Meeting < 2001, Geneva, Switzerland> |
| building | Verbundindex |
| bvnumber | BV044122737 |
| collection | ZDB-30-PAD |
| contents | 505 0 Introduction -- General. Developments in biological standardization. Bioterrorism. International nonproprietary names for biotechnology-derived medicinal products -- International guidelines, recommendations, and other matters related to the manufacture and quality control of biologicals. Guidelines on clinical evaluation of vaccines: regulatory expectations. Group C meningococcal conjugate vaccines. Inactivated oral cholera vaccines. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. Pneumococcal conjugate vaccines. Potency assays for diphtheria and tetanus vaccines. Pertussis vaccines. Preventive human immunodeficiency virus vaccines. Cell substrate safety. Cell banks. Yellow fever. Poliomyelitis vaccine, oral. Transmissible spongiform encephalitis and the safety of biologicals. Antivenoms. Gene therapy. Discontinuation requirements -- |
| ctrlnum | (ZDB-30-PAD)EBC284745 (ZDB-89-EBL)EBL284745 (OCoLC)317384275 (DE-599)BVBBV044122737 |
| dewey-full | 615.1901 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1901 |
| dewey-search | 615.1901 |
| dewey-sort | 3615.1901 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02279nmm a2200373zcb4500</leader><controlfield tag="001">BV044122737</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170217s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9241209240</subfield><subfield code="9">92-4-120924-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC284745</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL284745</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)317384275</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044122737</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1901</subfield><subfield code="2">22</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">WHO Expert Committee on Biological Standardization</subfield><subfield code="b">Meeting < 2001, Geneva, Switzerland></subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">WHO Expert Committee on Biological Standardization</subfield><subfield code="b">fifty-second report</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Geneva</subfield><subfield code="b">World Health Organization</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">vii, 232 p.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Technical report series (World Health Organization)</subfield><subfield code="v">924</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"The WHO Expert Committee on Biological Standardization met in Geneva from 26 to 30 November 2001"--Introd</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">505 0 Introduction -- General. Developments in biological standardization. Bioterrorism. International nonproprietary names for biotechnology-derived medicinal products -- International guidelines, recommendations, and other matters related to the manufacture and quality control of biologicals. Guidelines on clinical evaluation of vaccines: regulatory expectations. Group C meningococcal conjugate vaccines. Inactivated oral cholera vaccines. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. Pneumococcal conjugate vaccines. Potency assays for diphtheria and tetanus vaccines. Pertussis vaccines. Preventive human immunodeficiency virus vaccines. Cell substrate safety. Cell banks. Yellow fever. Poliomyelitis vaccine, oral. Transmissible spongiform encephalitis and the safety of biologicals. Antivenoms. Gene therapy. Discontinuation requirements -- </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological products</subfield><subfield code="x">Standards</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Standards</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PAD</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029529582</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| id | DE-604.BV044122737 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:44:22Z |
| institution | BVB |
| isbn | 9241209240 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029529582 |
| oclc_num | 317384275 |
| open_access_boolean | |
| physical | vii, 232 p. |
| psigel | ZDB-30-PAD |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | World Health Organization |
| record_format | marc |
| series2 | Technical report series (World Health Organization) |
| spelling | WHO Expert Committee on Biological Standardization Meeting < 2001, Geneva, Switzerland> Verfasser aut WHO Expert Committee on Biological Standardization fifty-second report Geneva World Health Organization 2004 vii, 232 p. txt rdacontent c rdamedia cr rdacarrier Technical report series (World Health Organization) 924 "The WHO Expert Committee on Biological Standardization met in Geneva from 26 to 30 November 2001"--Introd Includes bibliographical references 505 0 Introduction -- General. Developments in biological standardization. Bioterrorism. International nonproprietary names for biotechnology-derived medicinal products -- International guidelines, recommendations, and other matters related to the manufacture and quality control of biologicals. Guidelines on clinical evaluation of vaccines: regulatory expectations. Group C meningococcal conjugate vaccines. Inactivated oral cholera vaccines. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. Pneumococcal conjugate vaccines. Potency assays for diphtheria and tetanus vaccines. Pertussis vaccines. Preventive human immunodeficiency virus vaccines. Cell substrate safety. Cell banks. Yellow fever. Poliomyelitis vaccine, oral. Transmissible spongiform encephalitis and the safety of biologicals. Antivenoms. Gene therapy. Discontinuation requirements -- Biological products Standards Congresses Drugs Standards Congresses (DE-588)1071861417 Konferenzschrift gnd-content |
| spellingShingle | WHO Expert Committee on Biological Standardization fifty-second report 505 0 Introduction -- General. Developments in biological standardization. Bioterrorism. International nonproprietary names for biotechnology-derived medicinal products -- International guidelines, recommendations, and other matters related to the manufacture and quality control of biologicals. Guidelines on clinical evaluation of vaccines: regulatory expectations. Group C meningococcal conjugate vaccines. Inactivated oral cholera vaccines. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. Pneumococcal conjugate vaccines. Potency assays for diphtheria and tetanus vaccines. Pertussis vaccines. Preventive human immunodeficiency virus vaccines. Cell substrate safety. Cell banks. Yellow fever. Poliomyelitis vaccine, oral. Transmissible spongiform encephalitis and the safety of biologicals. Antivenoms. Gene therapy. Discontinuation requirements -- Biological products Standards Congresses Drugs Standards Congresses |
| subject_GND | (DE-588)1071861417 |
| title | WHO Expert Committee on Biological Standardization fifty-second report |
| title_auth | WHO Expert Committee on Biological Standardization fifty-second report |
| title_exact_search | WHO Expert Committee on Biological Standardization fifty-second report |
| title_full | WHO Expert Committee on Biological Standardization fifty-second report |
| title_fullStr | WHO Expert Committee on Biological Standardization fifty-second report |
| title_full_unstemmed | WHO Expert Committee on Biological Standardization fifty-second report |
| title_short | WHO Expert Committee on Biological Standardization |
| title_sort | who expert committee on biological standardization fifty second report |
| title_sub | fifty-second report |
| topic | Biological products Standards Congresses Drugs Standards Congresses |
| topic_facet | Biological products Standards Congresses Drugs Standards Congresses Konferenzschrift |
| work_keys_str_mv | AT whoexpertcommitteeonbiologicalstandardizationmeeting2001genevaswitzerland whoexpertcommitteeonbiologicalstandardizationfiftysecondreport |